From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab – Part 2
If you could run an experiment in your computer instead of the lab—and it actually gave you answers worth acting on—would you try it?
From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab – Part 1
Imagine trimming years off biologics development—and catching problematic formulations long before the first pipette is even picked up.
When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency – Part 2
What happens when therapeutic innovation meets real patient urgency?
When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency – Part 1
Real urgency in healthcare means balancing safety, impact, and accessibility—not just speeding to market.
From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments – Part 2
The biotech community is in continuous transformation. The landscape we navigate today will be dramatically different a decade from now, just as it was a decade ago.
From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments – Part 1
What does it take to build an innovation culture in one of the world’s most careful—and consequential—industries?
Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision – Part 2
Imagine unlocking a biological sample and, instead of peering under the usual “streetlight” of targeted analysis, being able to illuminate the entire landscape of metabolites, glycans, and unknown impurities.
Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision – Part 1
The identification and characterization of biological molecules is central to the biotech industry, particularly in drug development, bioprocess optimization, and advanced analytics.
Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale – Part 2
How do you actually measure and shrink your true environmental impact, when most data is missing and every facility operates on a different baseline?
Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale – Part 1
Is your manufacturing strategy bleeding money in ways you can’t see?